A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants with Atypical Hemolytic Uremic Syndrome (aHUS)
Phase 3
Recruiting
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Registration Number
- JPRN-jRCT2031210061
- Lead Sponsor
- Camelia Sima
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Body weight >=40 kg at screening
Vaccination against Neisseria meningitidis
Participants with a prior kidney transplant are eligible if they have a know history of complement-medical aHUS prior to the kidney transplant.
Exclusion Criteria
TMA associated with non-aHUS related renal disease
Positive direct Coombs test
Chronic dialysis and/or end stage renal disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method